氨己烯酸片(喜保宁)国内上市了吗

On August 21, 2009, the US FDA approved (Vigabatrin) as a monotherapy for pediatric patients aged 1 month to 2 years old. Its potential benefits for infantile spasms outweigh the potential risk of vision loss, and as an adjuvant treatment for adult patients with refractory complex partial epilepsy (CPS).

On January 16, 2019, the FDA approved the launch of a generic version of generic vigabatrin tablets (Vigabatrin). Vigabatrin tablets (Vigabatrin) are sold under the brand name Sabril in Canada, Mexico, and the United Kingdom. The Danish brand name is Sabrilex.

It is understood that vigabatrin tablets (Vigabatrin) are only available in a few countries, and the vigabatrin tablets (Vigabatrin) produced by Sanofi in France are cost-effective. Its specifications are 500 mg

Unfortunately, vigabatrin tablets (Vigabatrin) are not available in China.

Vigabatrin (vigabatrin), also known as vigabatrin, is a chemical. The chemical name is 4-amino-5-hexenoic acid, the molecular formula is C6H11NO2, and the molecular weight is 129.15700. Vigabatrin is an anti-epileptic drug and is clinically used to 1. Treat epilepsy in which other anti-epileptic drugs are ineffective, especially partial seizures. 2. It can also treat infantile spasms (West syndrome, West syndrome). It is absorbed rapidly after oral administration, and the peak value of the drug in blood can be reached 2 hours after taking it. t1/2 is 5~7h. It is mainly excreted in the urine, and about 65% of the administered dose is excreted in the urine as the original drug within the first 24 hours. Plasma protein binding is not significant.

Common adverse reactions with vigabatrin (vigabatrin) include fatigue, drowsiness, headache, dizziness, confusion, and depression. 2. Occasional aggressive behavior and psychosis (more common in patients with a history of mental illness and behavioral problems), memory loss, diplopia, weight gain, gastrointestinal disorders, edema and hair loss. 3. Nystagmus, nervousness, irritability, ataxia, paresthesia and tremor may also occur. 4. Some patients develop irreversible visual field defects, retinal lesions such as peripheral retinal atrophy, and more rarely, optic neuritis and atrophy. 5. Mentally, agitation, aggressive behavior, and paranoia may occur, and may occur in people with or without a history of mental illness. Mania or psychosis is also rare. 7. Hemoglobin and transaminase values ​​may decrease.

Patients must consult a doctor before using (Vigabatrin) to understand the side effects of the drug and take countermeasures.

Recommended related hot articles: /newsDetail/84681.html